At Large: Why didn’t Novartis try to conceal its ongoing bribery?
I’m not defending what Novartis did or trying to find an excuse for the company. It violated the FCPA, and (along with a former subsidiary) paid nearly $347 million in penalties and disgorgement to resolve the offenses.… Continue Reading